Gomiliximab Biosimilar - Anti-FCER2 mAb - Research Grade
Source
CAS 357613-86-6
Species
Humanized
Expression system
XtenCHO
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Gomiliximab,GOMILIXIMAB, LUMILIXIMAB, IDEC-152, PRIMATIZED ANTI-CD23, ST-152, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER,FCER2,anti-FCER2
Reference
PX-TA1671
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1,Kappa
Clonality
Monoclonal Antibody
Description of Gomiliximab Biosimilar - Anti-FCER2 mAb - Research Grade
The Structure of Gomiliximab Biosimilar
Gomiliximab Biosimilar, also known as Anti-FCER2 mAb, is a monoclonal antibody that is structurally similar to the human immunoglobulin G (IgG) antibody. It is a recombinant protein that is produced in a laboratory setting using advanced biotechnology techniques. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, connected by disulfide bonds.
The heavy chains of Gomiliximab Biosimilar consist of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH). The light chains contain two constant regions (CL) and one variable region (VL). The variable regions of both the heavy and light chains are responsible for binding to the target antigen, FCER2.
The Activity of Gomiliximab Biosimilar
Gomiliximab Biosimilar specifically targets the FCER2 protein, also known as the low-affinity immunoglobulin E (IgE) receptor. This receptor is found on the surface of immune cells, such as mast cells and basophils, and is involved in allergic reactions. When an allergen binds to IgE on these cells, it triggers the release of inflammatory mediators, leading to symptoms like itching, swelling, and difficulty breathing.
By binding to FCER2, Gomiliximab Biosimilar blocks the interaction between IgE and the receptor, preventing the release of inflammatory mediators. This reduces the severity of allergic reactions and provides relief from symptoms. In addition, Gomiliximab Biosimilar can also induce the death of FCER2-expressing cells, further reducing the inflammatory response.
Applications of Gomiliximab Biosimilar
Gomiliximab Biosimilar has potential applications in the treatment of various allergic and inflammatory conditions, such as asthma, atopic dermatitis, and allergic rhinitis. It is currently being developed as a biosimilar to omalizumab, a FDA-approved anti-IgE antibody, and has shown promising results in preclinical studies.
In addition to its therapeutic potential, Gomiliximab Biosimilar can also be used in research settings to study the role of FCER2 in allergic and inflammatory diseases. Its specificity for FCER2 makes it a valuable tool for understanding the mechanisms of these conditions and developing new treatments.
Conclusion
In summary, Gomiliximab Biosimilar, also known as Anti-FCER2 mAb, is a recombinant monoclonal antibody that specifically targets the low-affinity IgE receptor, FCER2. Its structure, composed of two heavy chains and two light chains, allows it to bind to FCER2 and block the release of inflammatory mediators. This makes it a promising candidate for the treatment of allergic and inflammatory diseases, as well as a valuable tool for research purposes.
Reviews
There are no reviews yet.